The effect of bupivacaine on myocardial tissue hypoxia and acidosis during ventricular fibrillation.
Previously we observed that during bupivacaine-induced circulatory collapse, myocardial tissue pH declined more slowly than expected. Here we evaluated the effect of bupivacaine on myocardial acidosis induced by ventricular fibrillation. Sixteen dogs were anesthetized with 1.5% end-tidal isoflurane, the chest was opened, and a probe that measured oxygen pressure (PmO(2)), carbon dioxide pressure, pH, and temperature was inserted into myocardial tissue. After baseline measures, each dog received either 10 mg/kg bupivacaine (n = 8) or a sham saline treatment (n = 8). Three minutes later ventricular fibrillation was initiated electrically, and the rate of change in PmO(2) and pH during ventricular fibrillation was measured. Baseline physiological measures were similar in the two groups of dogs. During ventricular fibrillation there was a rapid decrease in PmO(2), and the rate of decrease was not different between sham- and bupivacaine-treated dogs. Tissue pH decreased during ventricular fibrillation, and the rate of decrease was 4 times faster in sham- compared with bupivacaine-treated dogs (P < 0.05). These results show that bupivacaine attenuated myocardial tissue acidosis during ventricular fibrillation. This potentially beneficial effect may be a result of bupivacaine's ability to inhibit myocardial lactate and carbon dioxide production. This suggests a potential clinical application of bupivacaine for myocardial preservation.


CONCLUSIONS
In this animal study pretreatment with bupivacaine attenuated the progression of myocardial acidosis during ventricular fibrillation. The dogs regained normal hemodynamic variables after lipid infusion. The findings suggest such that bupivacaine may protect the heart against ischemic acidosis.
Weinberg
Guy
G
Department of Anesthesiology, University of Illinois at Chicago College of Medicine and the Chicago VA Hospital Westside Division, Chicago, Illinois 60612, USA. guyw@uic.edu
Paisanthasan
Chanannait
C
Feinstein
Douglas
D
Hoffman
William
W
D000138:Acidosis / Q000378:metabolism* / Q000503:physiopathology; D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002045:Bupivacaine / Q000494:pharmacology*; D002245:Carbon Dioxide / Q000378:metabolism; D004285:Dogs; D004554:Electric Countershock; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D000860:Hypoxia / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects; D014693:Ventricular Fibrillation
D000779:Anesthetics, Local; D002245:Carbon Dioxide; D002045:Bupivacaine